Annual CFF
-$38.99 M
-$147.84 M-135.82%
December 31, 2023
Summary
- As of February 20, 2025, ADMA annual cash flow from financing activities is -$38.99 million, with the most recent change of -$147.84 million (-135.82%) on December 31, 2023.
- During the last 3 years, ADMA annual CFF has fallen by -$182.89 million (-127.10%).
- ADMA annual CFF is now -127.10% below its all-time high of $143.90 million, reached on December 31, 2020.
Performance
ADMA Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
-$25.47 M
-$25.11 M-6935.08%
September 30, 2024
Summary
- As of February 20, 2025, ADMA quarterly cash flow from financing activities is -$25.47 million, with the most recent change of -$25.11 million (-6935.08%) on September 30, 2024.
- Over the past year, ADMA quarterly CFF has stayed the same.
- ADMA quarterly CFF is now -125.16% below its all-time high of $101.20 million, reached on March 31, 2020.
Performance
ADMA Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
-$66.27 M
-$25.88 M-64.09%
September 30, 2024
Summary
- As of February 20, 2025, ADMA TTM cash flow from financing activities is -$66.27 million, with the most recent change of -$25.88 million (-64.09%) on September 30, 2024.
- Over the past year, ADMA TTM CFF has stayed the same.
- ADMA TTM CFF is now -137.44% below its all-time high of $177.03 million, reached on March 31, 2020.
Performance
ADMA TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
ADMA Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -135.8% | 0.0% | 0.0% |
| 3 y3 years | -127.1% | -140.6% | -160.9% |
| 5 y5 years | -190.8% | -140.6% | -160.9% |
ADMA Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -132.2% | at low | -140.6% | +34.7% | -152.4% | at low |
| 5 y | 5-year | -127.1% | at low | -125.2% | +34.7% | -137.4% | at low |
| alltime | all time | -127.1% | at low | -125.2% | +34.7% | -137.4% | at low |
ADMA Biologics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$25.47 M(+6935.1%) | -$66.27 M(+64.1%) |
| Jun 2024 | - | -$362.00 K(-75.0%) | -$40.39 M(+1.5%) |
| Mar 2024 | - | -$1.45 M(-96.3%) | -$39.79 M(+2.0%) |
| Dec 2023 | -$38.99 M(-135.8%) | -$38.99 M(-9473.8%) | -$38.99 M(-162.1%) |
| Sep 2023 | - | $416.00 K(+73.3%) | $62.75 M(+2.0%) |
| Jun 2023 | - | $240.00 K(-136.9%) | $61.49 M(+0.9%) |
| Mar 2023 | - | -$650.00 K(-101.0%) | $60.93 M(-44.0%) |
| Dec 2022 | $108.85 M(-10.1%) | $62.74 M(-7535.8%) | $108.85 M(+8.9%) |
| Sep 2022 | - | -$843.80 K(+164.5%) | $99.93 M(-8.3%) |
| Jun 2022 | - | -$319.00 K(-100.7%) | $108.97 M(-13.8%) |
| Mar 2022 | - | $47.27 M(-12.2%) | $126.47 M(+4.5%) |
| Dec 2021 | $121.05 M(-15.9%) | $53.82 M(+556.1%) | $121.05 M(+21.9%) |
| Sep 2021 | - | $8.20 M(-52.3%) | $99.29 M(-2.4%) |
| Jun 2021 | - | $17.18 M(-58.9%) | $101.72 M(+20.3%) |
| Mar 2021 | - | $41.84 M(+30.5%) | $84.54 M(-41.3%) |
| Dec 2020 | $143.90 M(+79.9%) | $32.06 M(+201.6%) | $143.90 M(+28.7%) |
| Sep 2020 | - | $10.63 M(<-9900.0%) | $111.83 M(+10.5%) |
| Jun 2020 | - | -$1700.00(-100.0%) | $101.19 M(-42.8%) |
| Mar 2020 | - | $101.20 M(<-9900.0%) | $177.03 M(+121.3%) |
| Dec 2019 | $80.00 M(+86.4%) | -$7700.00(+1.3%) | $80.00 M(-0.0%) |
| Sep 2019 | - | -$7600.00(-100.0%) | $80.01 M(+0.0%) |
| Jun 2019 | - | $75.84 M(+1715.6%) | $80.00 M(+69.9%) |
| Mar 2019 | - | $4.18 M(<-9900.0%) | $47.10 M(+9.7%) |
| Dec 2018 | $42.92 M(-29.3%) | -$500.00(-96.1%) | $42.92 M(-54.0%) |
| Sep 2018 | - | -$12.90 K(-100.0%) | $93.30 M(+1.8%) |
| Jun 2018 | - | $42.94 M(<-9900.0%) | $91.65 M(+48.1%) |
| Mar 2018 | - | -$4400.00(-100.0%) | $61.86 M(+1.8%) |
| Dec 2017 | $60.75 M | $50.37 M(-3128.6%) | $60.75 M(+485.7%) |
| Sep 2017 | - | -$1.66 M(-112.6%) | $10.37 M(-12.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2017 | - | $13.15 M(-1279.7%) | $11.84 M(-24.7%) |
| Mar 2017 | - | -$1.12 M(>+9900.0%) | $15.73 M(-6.6%) |
| Dec 2016 | $16.84 M(+61.9%) | -$3900.00(-98.0%) | $16.84 M(+0.3%) |
| Sep 2016 | - | -$198.90 K(-101.2%) | $16.78 M(-0.4%) |
| Jun 2016 | - | $17.04 M(<-9900.0%) | $16.85 M(<-9900.0%) |
| Mar 2016 | - | -$3700.00(-93.8%) | -$61.40 K(-100.6%) |
| Dec 2015 | $10.40 M(+6.2%) | -$59.30 K(-53.7%) | $10.40 M(-32.9%) |
| Sep 2015 | - | -$128.10 K(-198.8%) | $15.50 M(-0.5%) |
| Jun 2015 | - | $129.70 K(-98.8%) | $15.58 M(+0.7%) |
| Mar 2015 | - | $10.46 M(+107.6%) | $15.47 M(+57.9%) |
| Dec 2014 | $9.80 M(-64.6%) | $5.04 M(<-9900.0%) | $9.80 M(-68.8%) |
| Sep 2014 | - | -$49.10 K(-399.4%) | $31.43 M(-0.1%) |
| Jun 2014 | - | $16.40 K(-99.7%) | $31.44 M(-0.2%) |
| Mar 2014 | - | $4.79 M(-82.0%) | $31.50 M(+14.0%) |
| Dec 2013 | $27.63 M(+41.9%) | $26.67 M(<-9900.0%) | $27.63 M(+498.0%) |
| Sep 2013 | - | -$31.40 K(-145.7%) | $4.62 M(+0.2%) |
| Jun 2013 | - | $68.70 K(-92.6%) | $4.61 M(+8.7%) |
| Mar 2013 | - | $925.70 K(-74.7%) | $4.25 M(-78.2%) |
| Dec 2012 | $19.47 M(>+9900.0%) | $3.66 M(-9527.1%) | $19.47 M(+23.0%) |
| Sep 2012 | - | -$38.80 K(-87.0%) | $15.83 M(-0.3%) |
| Jun 2012 | - | -$299.00 K(-101.9%) | $15.87 M(-1.8%) |
| Mar 2012 | - | $16.15 M(>+9900.0%) | $16.17 M(>+9900.0%) |
| Dec 2011 | - | $15.00 K(+476.9%) | $34.60 K(+23.1%) |
| Sep 2011 | - | $2600.00(>+9900.0%) | $28.10 K(+10.2%) |
| Jun 2011 | $25.50 K(+10.9%) | $0.00(-100.0%) | $25.50 K(0.0%) |
| Mar 2011 | - | $17.00 K(+100.0%) | $25.50 K(+200.0%) |
| Dec 2010 | - | $8500.00(>+9900.0%) | $8500.00(>+9900.0%) |
| Sep 2010 | - | $0.00 | $0.00 |
| Jun 2010 | $23.00 K | - | - |
FAQ
- What is ADMA Biologics annual cash flow from financing activities?
- What is the all time high annual CFF for ADMA Biologics?
- What is ADMA Biologics annual CFF year-on-year change?
- What is ADMA Biologics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for ADMA Biologics?
- What is ADMA Biologics quarterly CFF year-on-year change?
- What is ADMA Biologics TTM cash flow from financing activities?
- What is the all time high TTM CFF for ADMA Biologics?
- What is ADMA Biologics TTM CFF year-on-year change?
What is ADMA Biologics annual cash flow from financing activities?
The current annual CFF of ADMA is -$38.99 M
What is the all time high annual CFF for ADMA Biologics?
ADMA Biologics all-time high annual cash flow from financing activities is $143.90 M
What is ADMA Biologics annual CFF year-on-year change?
Over the past year, ADMA annual cash flow from financing activities has changed by -$147.84 M (-135.82%)
What is ADMA Biologics quarterly cash flow from financing activities?
The current quarterly CFF of ADMA is -$25.47 M
What is the all time high quarterly CFF for ADMA Biologics?
ADMA Biologics all-time high quarterly cash flow from financing activities is $101.20 M
What is ADMA Biologics quarterly CFF year-on-year change?
Over the past year, ADMA quarterly cash flow from financing activities has changed by $0.00 (0.00%)
What is ADMA Biologics TTM cash flow from financing activities?
The current TTM CFF of ADMA is -$66.27 M
What is the all time high TTM CFF for ADMA Biologics?
ADMA Biologics all-time high TTM cash flow from financing activities is $177.03 M
What is ADMA Biologics TTM CFF year-on-year change?
Over the past year, ADMA TTM cash flow from financing activities has changed by $0.00 (0.00%)